Close Menu

NEW YORK (GenomeWeb) – The litigants in an intellectual property lawsuit over liquid biopsy technology have each levied misconduct allegations against the other.

Personal Genome Diagnostics (PGDx) has alleged that Guardant Health improperly obtained at least three patents for liquid biopsy technology. And Guardant has suggested that PGDx's "infringement of the patents-in-suit is deliberate and willful and constitutes egregious misconduct."

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Qiagen: Nov 16, 2014

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 


This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.

Sponsored by
Thermo Fisher Scientific

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.